ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1211

Relationship Between Changes in Lipid Levels and Improvement in Disease Activity Outcomes in Patients with Rheumatoid Arthritis Receiving Upadacitinib Treatment: Pooled Analysis of Data from Two Phase 3 Studies
Abstract Number: 1600

Relationship Between Electronic Health Record Vendor and Performance on Patient-reported Outcome Quality Measures in the ACR’s Rheumatology Informatics System for Effectiveness (RISE) Registry
Abstract Number: 0484

Relationship Between Paraoxonase-1 Genotype, Activity, and Major Adverse Cardiovascular Events in Patients with Rheumatoid Arthritis Receiving Tofacitinib
Abstract Number: 0491

Relationship Between Rheumatoid Arthritis and Pulmonary Function in the UK Biobank
Abstract Number: 1020

Relationship Between Skin-related Quality of Life, Psychosocial Stress, and Race in Cutaneous Lupus Erythematosus
Abstract Number: 1112

Relationship of Depth-Specific Subchondral Bone Mineral Density and Pain in Knee Osteoarthritis: The Multicenter Osteoarthritis Study
Abstract Number: 1337

Relationship of the Pro12Ala Polymorphism of the PPARg Gene with Inflammatory Activity, Osteoporosis and Obesity in Patients with Psoriatic Arthritis
Abstract Number: 0694

Relationships Among Adherence and Patient Outcomes in a Cognitive Behavioral Plus Physical Activity Intervention for Older Adults with Osteoarthritis and Hypertension
Abstract Number: 0158

Relationships Between Disease Patterns in RA and Rheumatology Treatment
Abstract Number: 1872

Relative Associations of Sociodemographic, Clinical and HLA-B Alleles with Enthesitis and Peripheral Arthritis in Patients with Ankylosing Spondylitis
Abstract Number: 0943

Reliability and Validity Issues in Fibromyalgia Diagnosis
Abstract Number: 1168

Reliability and Validity of a New Skin Activity Measure for Localized Scleroderma
Abstract Number: 1889

Reliability and Validity of the PROMIS-29 Health Profile in Ankylosing Spondylitis Patients
Abstract Number: 1132

Reliability of Virtual Sources of Education for Patients with Vasculitis
Abstract Number: 1375

Remission in Axial Spondyloarthritis: Is There a Difference Between NSAIDs and Biologics in the Real Life?

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].